海翔药业(002099) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥575,373,970.84, a decrease of 30.84% compared to ¥831,903,896.72 in the same period last year[10] - Net profit attributable to shareholders was ¥105,120,332.86, down 48.08% from ¥202,484,692.73 year-on-year[10] - The net profit after deducting non-recurring gains and losses was ¥100,536,464.90, a decline of 47.99% compared to ¥193,305,262.65 in the previous year[10] - Basic and diluted earnings per share were both ¥0.06, down 53.85% from ¥0.13 in the previous year[10] - The total comprehensive income for the current period was ¥105,323,401.65, a decrease from ¥202,839,941.60 in the previous period[68] - The total net profit for the current period is ¥1,566,972.57, a significant decrease from ¥25,743,261.88 in the previous period, reflecting a decline of approximately 93.9%[76] - Operating profit for the current period is ¥2,078,635.19, down from ¥27,341,739.55, indicating a decrease of about 92.4%[76] Cash Flow - The net cash flow from operating activities increased by 55.33% to ¥188,208,215.04, compared to ¥121,163,063.50 in the same period last year[10] - Cash flow from operating activities generated a net amount of ¥188,208,215.04, compared to ¥121,163,063.50 in the previous period, showing an increase of approximately 55.4%[79] - The company incurred a total of ¥309,190,834.38 in cash outflows from operating activities, down from ¥543,951,813.68, indicating a decrease of approximately 43.1%[79] - The company reported cash outflows from financing activities totaling ¥498,667,291.91, compared to ¥224,102,697.03 in the previous period, indicating an increase of approximately 122.3%[82] - The company’s cash flow from investment activities resulted in a net outflow of ¥24,844,525.27, compared to a net inflow of ¥295,643,069.92 in the previous period[79] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,350,342,221.17, a decrease of 5.88% from ¥6,747,198,664.47 at the end of the previous year[10] - Total current assets decreased to CNY 2,725,400,236.21 from CNY 3,062,429,817.76, reflecting a decline in liquidity[43] - The company's accounts receivable financing increased by 43.04% to CNY 106,609,056.29, attributed to an increase in bank acceptance bills received during the period[27] - Current liabilities decreased from ¥940,281,788.69 to ¥906,768,993.21, a reduction of approximately 3.6%[49] - Total liabilities decreased from ¥1,022,736,568.92 to ¥987,269,533.47, reflecting a decline of about 3.5%[49] - Owner's equity decreased from ¥5,724,462,095.55 to ¥5,363,072,687.70, a decrease of approximately 6.3%[52] Expenses - The company's management expenses rose by 30.07% to CNY 123,334,176.67, mainly due to increased depreciation, repairs, and labor costs[27] - The company's income tax expenses decreased by 44.90% to CNY 18,848,950.55, primarily due to a reduction in total profit[27] - Research and development expenses were ¥25,833,575.74, down 14.5% from ¥30,305,725.69 in the previous period[62] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 77,179[13] - The company reported a basic earnings per share of ¥0.06, compared to ¥0.13 in the previous period[68] Accounting Changes - The first quarter report for 2020 was not audited, indicating preliminary financial data[100] - The company is implementing new revenue and lease accounting standards starting in 2020, affecting prior comparative data[100]